Compare Davita Inc (DVA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Toronto-Dominion Bank — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Toronto-Dominion Bank trades at $121.35 (market cap $199.91B). The key difference: Toronto-Dominion Bank is far larger — about 17.1× Davita Inc's market cap, and Toronto-Dominion Bank pays a 2.64% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TD | |
|---|---|---|
Market Cap | $11.72B | $199.91B |
Sector | Health | Financials |
52-Week High | $240.96 | $124.80 |
52-Week Low | $103.87 | $72.85 |
Enterprise Value | $24.44B | — |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
TD stock trades at $121.31, up 0.11% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.74, exceeding the $1.63 estimate, and maintains a strong net income margin of 23.38%. Analyst consensus is positive with 9 buy ratings and no sell ratings among 17 analysts. Recent news highlights value comparisons with peers and dividend stability.
Outlook remains favorable due to consistent earnings performance and robust profitability, though risks include high debt levels and potential regulatory scrutiny. The stock's valuation at a P/E of 19.95 is reasonable relative to historical margins, supporting a cautious bullish view for long-term investors seeking dividend income and steady growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
